Short-term kinetics of tumor antigen expression in response to vaccination

G. A. Ohnmacht, E. Wang, S. Mocellin, A. Abati, A. Filie, P. Fetsch, A. I. Riker, U. S. Kammula, S. A. Rosenberg, F. M. Marincola

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

The melanoma patient's immune response to tumor has been extensively studied. Yet, the frequently observed coexistence of tumor-associated Ag (TAA)-specific T cells with their target cells in vivo remains unexplained. Loss of TAA expression might contribute to this paradox. We studied TAA expression in metastases by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and soon after immunotherapy. Limitations due to low amounts of starting material were overcome with a high fidelity antisense RNA amplification method. TAA expression was measured by quantitative real-time PCR of anti-sense RNA. Decrease in gp100/Pmel-17 TAA preceded tumor disappearance in several instances and could be best explained by immune selection because most patients had received gp100/Pmel-17-specific vaccination. Conversely, immune selection was absent in nonregressing lesions. These observations suggest that vaccination, when successful, triggers a broad inflammatory reaction that can lead to tumor destruction despite immune selection. Additionally, lack of clinical response might be attributed to lack of this initiating event rather than immune escape. This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy.

Original languageEnglish
Pages (from-to)1809-1820
Number of pages12
JournalJournal of Immunology
Volume167
Issue number3
Publication statusPublished - 1 Aug 2001
Externally publishedYes

Fingerprint

Neoplasm Antigens
Vaccination
Neoplasms
Antisense RNA
Melanoma
Fine Needle Biopsy
Immunotherapy
Real-Time Polymerase Chain Reaction
Neoplasm Metastasis
T-Lymphocytes
Gene Expression

ASJC Scopus subject areas

  • Immunology

Cite this

Ohnmacht, G. A., Wang, E., Mocellin, S., Abati, A., Filie, A., Fetsch, P., ... Marincola, F. M. (2001). Short-term kinetics of tumor antigen expression in response to vaccination. Journal of Immunology, 167(3), 1809-1820.

Short-term kinetics of tumor antigen expression in response to vaccination. / Ohnmacht, G. A.; Wang, E.; Mocellin, S.; Abati, A.; Filie, A.; Fetsch, P.; Riker, A. I.; Kammula, U. S.; Rosenberg, S. A.; Marincola, F. M.

In: Journal of Immunology, Vol. 167, No. 3, 01.08.2001, p. 1809-1820.

Research output: Contribution to journalArticle

Ohnmacht, GA, Wang, E, Mocellin, S, Abati, A, Filie, A, Fetsch, P, Riker, AI, Kammula, US, Rosenberg, SA & Marincola, FM 2001, 'Short-term kinetics of tumor antigen expression in response to vaccination', Journal of Immunology, vol. 167, no. 3, pp. 1809-1820.
Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P et al. Short-term kinetics of tumor antigen expression in response to vaccination. Journal of Immunology. 2001 Aug 1;167(3):1809-1820.
Ohnmacht, G. A. ; Wang, E. ; Mocellin, S. ; Abati, A. ; Filie, A. ; Fetsch, P. ; Riker, A. I. ; Kammula, U. S. ; Rosenberg, S. A. ; Marincola, F. M. / Short-term kinetics of tumor antigen expression in response to vaccination. In: Journal of Immunology. 2001 ; Vol. 167, No. 3. pp. 1809-1820.
@article{773e5de865ed4944aabb75cf5e41d5f5,
title = "Short-term kinetics of tumor antigen expression in response to vaccination",
abstract = "The melanoma patient's immune response to tumor has been extensively studied. Yet, the frequently observed coexistence of tumor-associated Ag (TAA)-specific T cells with their target cells in vivo remains unexplained. Loss of TAA expression might contribute to this paradox. We studied TAA expression in metastases by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and soon after immunotherapy. Limitations due to low amounts of starting material were overcome with a high fidelity antisense RNA amplification method. TAA expression was measured by quantitative real-time PCR of anti-sense RNA. Decrease in gp100/Pmel-17 TAA preceded tumor disappearance in several instances and could be best explained by immune selection because most patients had received gp100/Pmel-17-specific vaccination. Conversely, immune selection was absent in nonregressing lesions. These observations suggest that vaccination, when successful, triggers a broad inflammatory reaction that can lead to tumor destruction despite immune selection. Additionally, lack of clinical response might be attributed to lack of this initiating event rather than immune escape. This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy.",
author = "Ohnmacht, {G. A.} and E. Wang and S. Mocellin and A. Abati and A. Filie and P. Fetsch and Riker, {A. I.} and Kammula, {U. S.} and Rosenberg, {S. A.} and Marincola, {F. M.}",
year = "2001",
month = "8",
day = "1",
language = "English",
volume = "167",
pages = "1809--1820",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Short-term kinetics of tumor antigen expression in response to vaccination

AU - Ohnmacht, G. A.

AU - Wang, E.

AU - Mocellin, S.

AU - Abati, A.

AU - Filie, A.

AU - Fetsch, P.

AU - Riker, A. I.

AU - Kammula, U. S.

AU - Rosenberg, S. A.

AU - Marincola, F. M.

PY - 2001/8/1

Y1 - 2001/8/1

N2 - The melanoma patient's immune response to tumor has been extensively studied. Yet, the frequently observed coexistence of tumor-associated Ag (TAA)-specific T cells with their target cells in vivo remains unexplained. Loss of TAA expression might contribute to this paradox. We studied TAA expression in metastases by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and soon after immunotherapy. Limitations due to low amounts of starting material were overcome with a high fidelity antisense RNA amplification method. TAA expression was measured by quantitative real-time PCR of anti-sense RNA. Decrease in gp100/Pmel-17 TAA preceded tumor disappearance in several instances and could be best explained by immune selection because most patients had received gp100/Pmel-17-specific vaccination. Conversely, immune selection was absent in nonregressing lesions. These observations suggest that vaccination, when successful, triggers a broad inflammatory reaction that can lead to tumor destruction despite immune selection. Additionally, lack of clinical response might be attributed to lack of this initiating event rather than immune escape. This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy.

AB - The melanoma patient's immune response to tumor has been extensively studied. Yet, the frequently observed coexistence of tumor-associated Ag (TAA)-specific T cells with their target cells in vivo remains unexplained. Loss of TAA expression might contribute to this paradox. We studied TAA expression in metastases by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and soon after immunotherapy. Limitations due to low amounts of starting material were overcome with a high fidelity antisense RNA amplification method. TAA expression was measured by quantitative real-time PCR of anti-sense RNA. Decrease in gp100/Pmel-17 TAA preceded tumor disappearance in several instances and could be best explained by immune selection because most patients had received gp100/Pmel-17-specific vaccination. Conversely, immune selection was absent in nonregressing lesions. These observations suggest that vaccination, when successful, triggers a broad inflammatory reaction that can lead to tumor destruction despite immune selection. Additionally, lack of clinical response might be attributed to lack of this initiating event rather than immune escape. This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy.

UR - http://www.scopus.com/inward/record.url?scp=0035423414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035423414&partnerID=8YFLogxK

M3 - Article

C2 - 11466407

AN - SCOPUS:0035423414

VL - 167

SP - 1809

EP - 1820

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -